natgillin/translations-raw huggingface dataset:
vandladningsforstyrrelser
urination disorders
Vandladningshyppighed og/eller retention (B)
Urinary frequency and/or retention (B)
vandladningslidelser, urinvejsinfektion,
urination disorders, urinary tract infection,
Vandladningsproblemer
Problems passing urine
Vandladningsproblemer, nykturi, øget vandladningsfrekvens
Micturition disorder, nocturia, increased urinary frequency
vandophobning
water retention
Vandopløselig quinolingult farve (E 104)
Quinoline yellow WS dye (E104)
Vandtætte handsker bør anvendes ved præparation og under bestemmelsen af radiokemisk renhed af [90Y]-mærket Zevalin.
Waterproof gloves must be utilised in the preparation and during the determination of radiochemical purity of [90Y]-radiolabelled Zevalin.
vangerskabsforebyggende lægemidler (kontraceptiva), der indeholder hormoner, fx piller, injektioner eller plastre
birth control medicines (contraceptives) containing hormones, such as pills, injections, or patches
Vaniljearoma (indeholdende parahydroxybenzoesyre, parahydroxybenzaldehyd, vanillinsyre, vanillin, heliotrop, ethylvanillin),
vanilla flavour (containing p-hydroxybenzoic acid, p-hydroxybenzaldehyde, vanillic acid, vanillin, heliotrope, ethyl vanillin),
Vanillesmag (indeholder propylenglycol)
Vanilla flavour (contains propylene glycol)
Vaniqa kan som al anden medicin give bivirkninger, men ikke alle får bivirkninger.
Like all medicines, Vaniqa can cause side effects, although not everybody gets them.
Vaniqa påvirker ikke eller i ubetydelig grad evnen til at føre motorkøretøj eller betjene maskiner.
Vaniqa has no or negligible effects on the ability to drive and use machines.
Vaniqas sikkerhed og virkning hos børn i alderen 0-18 år er ikke klarlagt.
The safety and efficacy of Vaniqa in children 0-18 years has not been established.
Vanskelig og smertefuld vandladning
Difficulty and pain when passing urine
vanskelig og smertefuld vandladning – dette kan være tegn på blæreobstruktion eller urinretention.
difficulty and pain when passing urine – these may be signs of a bladder obstruction or urinary retention.
vanskelig, smertefuld menstruation
difficult, painful menstruation
vanskelighed med at kontrollere kroppens bevægelser, ufrivillige bevægelser;
movements, hyperkinesia (hyperactivity);
vanskelighed ved at falde i søvn (søvnløshed)
difficulty falling asleep (insomnia)
Vanskelighed ved at få erektion
Difficulty getting an erection
vanskelighed ved at holde sig i ro
feeling unable to keep still
Vanskelighed ved at tænke og koncentrere sig, depression.
Difficulty in thinking and concentrating, depression.
Vanskelighed ved at tænke og koncentrere sig, depression.
Difficulty thinking and concentrating, depression.
Vanskelighed ved eller smertefuld vandladning, inkontinens.
Difficulty with or painful urination, incontinence
Vanskelighed ved eller smertefuld vandladning, inkontinens.
Difficulty with or painful urination, incontinence.
Vanskeligheder med at falde i søvn om aftenen, midt om natten eller sidst på natten, for tidlig opvågning, overdreven søvnighed, døsighed
Difficulty in falling asleep at the beginning of the night or in the middle of the night or at the end of the night, difficulty in staying asleep, excessive sleepiness, somnolence
Vanskeligheder med at få eller opretholde erektion
Difficulty in getting or keeping an erection
vanskeligheder med at få eller opretholde erektion (impotens)
difficulties in getting or maintaining an erection (erectile dysfunction).
vanskeligheder med bevægeapparatet eller manglende følesans
difficulties with body movements
vanskeligt at forudse
tipranavir/r
VANTAVO 70 mg/2.800 IE tabletter Alendronsyre/cholecalciferol
VANTAVO 70 mg/2800 IU tablets Alendronic acid /colecalciferol
VANTAVO 70 mg/2.800 IE tabletter er kapselformede hvide/beige tabletter mærket med omridset af en knogle på den ene side og ”710” på den anden side.
VANTAVO 70 mg/2800 IU tablets are available as capsule-shaped, white to off-white tablets marked with an outline of a bone image on one side and ‘710’ on the other.
VANTAVO 70 mg/2.800 IE, tabletter
VANTAVO 70 mg/2800 IU tablets
VANTAVO 70 mg/2800 IE
VANTAVO 70 mg/2800 IU
Vantavo 70 mg/5 600 IE anvendes til patienter, der ikke tager vitamin D- tilskud.
Vantavo 70 mg/5,600 IU is for use in patients who are not taking vitamin D supplements.
VANTAVO 70 mg/5.600 IE er rektangulære, hvide/beige tabletter med afrundede hjørner og mærket med omridset af en knogle på den ene side og ”270” på den anden side.
VANTAVO 70 mg/5600 IU tablets are available as modified rectangle-shaped, white to off-white tablets marked with an outline of a bone image on one side and ‘270’ on the other.
VANTAVO 70 mg/5.600 IE tabletter Alendronsyre/cholecalciferol
VANTAVO 70 mg/5600 IU tablets Alendronic acid /colecalciferol
VANTAVO 70 mg/5.600 IE, tabletter
VANTAVO 70 mg/5600 IU tablets
VANTAVO 70 mg/5600 IE
VANTAVO 70 mg/5600 IU
VANTAVO bør ikke gives til børn og unge under 18 år.
VANTAVO should not be given to children and adolescents less than 18 years of age.
VANTAVO bør ikke gives til børn under 18 år, da der ikke foreligger data vedrørende kombinationen alendronsyre/cholecalciferol.
VANTAVO should not be used in children less than 18 years of age because no data are available for the alendronic acid/colecalciferol combination.
VANTAVO er en kombinationstablet indeholdende de to aktive substanser alendronatnatriumtrihydrat og cholecalciferol (D3-vitamin).
VANTAVO is a combination tablet containing the two active substances alendronate sodium trihydrate and colecalciferol (vitamin D3).
VANTAVO er indiceret til behandling af postmenopausal osteoporose hos kvinder med risiko for D- vitaminmangel.
VANTAVO is indicated for the treatment of postmenopausal osteoporosis in women at risk of vitamin D insufficiency.
VANTAVO er indiceret til behandling af postmenopausal osteoporose hos kvinder, som ikke får tilskud af D-vitamin og med risiko for D-vitaminmangel.
VANTAVO is indicated for the treatment of postmenopausal osteoporosis in women who are not receiving vitamin D supplementation and are at risk of vitamin D insufficiency.
VANTAVO fås i pakninger med 2, 4 eller 12 tabletter.
VANTAVO is available in packs containing 2, 4 or 12 tablets.
VANTAVO fås i pakninger med 2, 4, 6 eller 12 tabletter.
VANTAVO is available in packs containing 2, 4, 6 or 12 tablets.
VANTAVO må ikke tages ved sengetid, eller før patienten er stået op om morgenen.
VANTAVO should not be taken at bedtime or before arising for the day.
VANTAVO nedsætter risikoen for hoftebrud og brud på rygsøjlen hos kvinder efter overgangsalderen.
VANTAVO reduces the risk of spine and hip fractures in women after menopause.
VANTAVO reducerer risikoen for vertebrale frakturer og hoftefrakturer.
VANTAVO reduces the risk of vertebral and hip fractures.
VANTAVO skal tages, efter patienten er stået op, og det skal tages sammen med et helt glas postevand (mindst 200 ml).
VANTAVO should only be swallowed after getting up for the day with a full glass of water (not less than 200 ml).
Vantavo1 alendronsyre og colecalciferol
Vantavo1 alendronic acid and colecalciferol
Vantobra 170 mg nebuliser-opløsning
Vantobra 170 mg nebuliser solution
Vantobra 170 mg nebuliser-opløsning Tobramycin
Vantobra 170 mg nebuliser solution Tobramycin
Vantobra er et “hybridt lægemiddel”.
Vantobra is a ‘hybrid medicine’.
Vantobra leveres i polyethylen (PE) ampuller, der er pakket i poser (8 ampuller pr. pose).
Vantobra is supplied in polyethylene (PE) ampoules that are packed in sealed aluminium foil pouches (8 ampoules per pouch).
Vantobra nebuliser-opløsning leveres i en ampul klar til brug.
Vantobra nebuliser solution is provided in a ready-to-use ampoule.
var 50 mg ved co-administration med
tudy was 50 mg when co-administered in
var i samme publikation oplysning om længere varende opfølgningsdata fra 12 MDS/MPD-patienter med PDGFR-omlejring (5 patienter fra studie B2225).
The same publication reported long term follow-up data from 12 MDS/MPD patients with PDGFR gene rearrangements (5 patients from study B2225).
var indinavirs og efavirenz'
Fosamprenavir/Saquinavir/
var let nedsat ved
was slightly decreased
Vardenafil
considered.
Vardenafil
Narcotic analgesics
Vardenafil
Not studied.
Vardenafil
Omeprazole
Vardenafil (mod pulmonal arteriel hypertension eller for at opnå eller bibeholde erektion)
Vardenafil (for pulmonary arterial hypertension (PAH), or for getting or keeping an erection)
Vardenafil 20 mg filmovertrukne tabletter forstærkede den hypotentive virkning af sublingual glyceryltrinitrat (0,4 mg) indtaget 1 og 4 timer efter vardenafil-administration hos raske midaldrende forsøgspersoner.
Vardenafil 20 mg film-coated tablets potentiated the blood pressure lowering effect of sublingual nitroglycerin (0.4 mg) taken 1 and 4 hours after vardenafil administration to healthy middle aged subjects.
Vardenafil 20 mg forstærkede den hypotentive effekt af sublingual nitroglycerin (0,4 mg) indtaget 1 og 4 timer efter vardenafil administration hos raske midaldrende forsøgspersoner.
Vardenafil 20 mg film-coated tablet potentiated the blood pressure lowering effect of sublingual nitroglycerin (0.4 mg) taken 1 and 4 hours after vardenafil administration to healthy middle aged subjects.
Vardenafil 5 mg, enkeltdosis 600 mg hver
administered Medicinal Products (mg)
Vardenafil absorberes hurtigt efter indgift af vardenafil 10 mg smeltetabletter uden vand.
Vardenafil is rapidly absorbed after administration of 10 mg orodispersible tablets without water.
Vardenafil absorberes hurtigt efter indgift af vardenafil 10 mg smeltetabletter uden vand.
Vardenafil is rapidly absorbed after administration of vardenafil 10 mg orodispersible tablets without water.
Vardenafil er kontraindiceret hos mænd over 75 år (se pkt.
Vardenafil is contraindicated in men older than 75 years old (see section 4.3).
vardenafil hos mænd over 75 år på grund af øget risiko for bivirkninger.
vardenafil in men older than 75-years due to increased risk of adverse events
vardenafil hos mænd over 75 år – lægemiddel til behandling af rejsningsbesvær hos voksne mænd visse lægemidler mod HIV: saquinavir/ritonavir, saquinavir visse lægemidler mod langvarig (kronisk) hepatitis C (smitsom leverbetændelse, som skyldes hepatitis C-virus): Paritaprevir/Ombitasvir (ritonavir) methadon: lægemiddel til behandling af stofafhængighed
vardenafil in men older than 75 years – medicine to treat erectile dysfunction in adults men certain medicines for HIV: saquinavir/ritonavir, saquinavir certain medicines to treat long-term (chronic) hepatitis C (an infectious disease that affects the liver, caused by the hepatitis C virus): Paritaprevir/Ombitasvir (ritonavir) methadone: medicine to treat dependence to drugs
Vardenafil i filmovertrukne tabletter metaboliseres hovedsagelig i leveren via cytokrom P450 (CYP)- isoformen 3A4 men også via CYP3A5- og CYP2C-isoformer.
Vardenafil in film-coated tablets is metabolised predominantly by hepatic metabolism via cytochrome P450 (CYP) isoform 3A4 with some contribution from CYP3A5 and CYP2C isoforms.
Vardenafil i filmovertrukne tabletter metaboliseres hovedsagelig i leveren via cytokrom P450 (CYP)- isoformen 3A4, men også via CYP3A5- og CYP2C-isoformer.
Vardenafil in film-coated tablets is metabolised predominantly by hepatic metabolism via cytochrome P450 (CYP) isoform 3A4 with some contribution from CYP3A5 and CYP2C isoforms.
Vardenafil i Vivanza filmovertrukne tabletter metaboliseres hovedsagelig i leveren via cytokrom P450 (CYP)-isoformen 3A4, men også via CYP3A5- og CYP2C-isoformer.
Vardenafil in Vivanza film-coated tablets is metabolised predominantly by hepatic metabolism via cytochrome P450 (CYP) isoform 3A4 with some contribution from CYP3A5 and CYP2C isoforms.
vardenafil til patienter, der får
inhibitors sildenafil or vardenafil in
Vardenafil øger kraftigt virkningen af endogen nitrogenoxid i corpus cavernosum ved at hæmme PDE5.
Vardenafil potently enhances the effect of endogenous nitric oxide in the corpus cavernosum by inhibiting PDE5.
Vardenafil, alene eller i kombination med acetylsalicylsyre, har ingen effekt på blødningstiden hos mennesker (se pkt.
In humans, vardenafil had no effect on bleeding time alone or in combination with acetylsalicyclic acid (see section 4.5).
Vardenafil, alene eller i kombination med acetylsalicylsyre, har ingen effekt på blødningstiden hos mennesker (se pkt.
In humans, vardenafil had no effect on bleeding time alone or in combination with acetylsalicylic acid (see section 4.5).
Vardenafil-dosis bør ikke overstige max.
Vardenafil dose should not exceed a maximum of
Vardenafil: AUC: ↑ 10 gange Cmax: ↑ 4 gange
Vardenafil: AUC: ↑ 10-fold Cmax: ↑ 4-fold
Vardenafil: AUC: ↑ 49-gange
AUC: ↑ 49-fold
Vardenafils lever-clearance hos raske ældre forsøgspersoner (65 år og derover) reduceredes sammenlignet med raske yngre forsøgspersoner (18-45 år).
Hepatic clearance of vardenafil in healthy elderly volunteers (65 years and over) was reduced as compared to healthy younger volunteers (18-45 years).
Varemærkenavnet på det administrerede lægemiddel skal noteres tydeligt i patientens journal for at forbedre sporbarheden af granulocyt-kolonistimulerende faktorer (G-CSF’er).
In order to improve the traceability of granulocyte-colony stimulating factors (G-CSFs), the trade name of the administered product should be clearly recorded in the patient file.
varende til protokollen.
4according to protocol
Vareniclin (n=1.130)
Varenicline (N=1130)
Vareniclin bør ikke anvendes under graviditet.
Varenicline is not recommended during pregnancy.
Vareniclin vs bupropion
Varenicline vs Bupropion
Vareniclin vs placebo
Varenicline vs Placebo
varer ved i > 4 uger, eller
persistent for > 4 weeks, or
varer ved i ≥ 4 uger, eller
persistent for ≥ 4 weeks, or
Vargatef 100 mg bløde kapsler er ferskenfarvede, uigennemsigtige, aflange kapsler med Boehringer Ingelheims logo og tallet “100” præget med sort på den ene side.
Vargatef 100 mg soft capsules are peach-coloured, opaque, oblong capsules imprinted on one side in black with the Boehringer Ingelheim company symbol and the figure “100”.
Vargatef 100 mg bløde kapsler er ikke nødvendigvis markedsført i alle pakningsstørrelser.
Not all pack-sizes of Vargatef 100 mg soft capsules may be marketed.
Vargatef 100 mg bløde kapsler fås i tre pakningsstørrelser:
Three pack-sizes of Vargatef 100 mg soft capsules are available:
Vargatef 100 mg bløde kapsler nintedanib
Vargatef 100 mg soft capsules nintedanib
Vargatef 100 mg bløde kapsler Vargatef 150 mg bløde kapsler
Vargatef 100 mg soft capsules Vargatef 150 mg soft capsules
Vargatef 100 mg kapsler nintedanib
Vargatef 100 mg capsules Nintedanib
Vargatef 150 mg bløde kapsler er brune, uigennemsigtige, aflange kapsler med Boehringer Ingelheims logo og tallet “150” præget med sort på den ene side.
Vargatef 150 mg capsules are brown-coloured, opaque, oblong capsules imprinted on one side in black with the Boehringer Ingelheim company symbol and the figure “150”.
Vargatef 150 mg bløde kapsler nintedanib
Vargatef 150 mg soft capsules nintedanib
Vargatef 150 mg kapsler nintedanib
Vargatef 150 mg capsules Nintedanib
Vargatef anvendes til behandling af en form for ikke-småcellet lungekræft (adenokarcinom), hvor kræften er lokalt fremskreden, har bredt sig fra udgangsstedet til andre dele af kroppen (er metastatisk) eller er vendt tilbage på det sted, hvor den oprindeligt er opstået (lokalt recidiv).
Vargatef is used to treat a type of non-small cell lung cancer called ‘adenocarcinoma’, when the cancer is locally advanced, metastatic (when cancer cells have spread from the original site to other parts of the body) or locally recurrent (when the cancer has come back in the same area).
Vargatef indeholder soja
Vargatef contains soya
Vargatefs sikkerhed og virkning hos børn i alderen 0-18 år er ikke klarlagt.
The safety and efficacy of Vargatef in children aged 0-18 years have not been established.
Variabel Type af estimat;
Variable Type of estimate;
Variabel Type af estimat; behandlings-
Variable Type of estimate; treatment
Variabilitet i eksponering kan også forekomme på grund af forskelle i indholdet i den gastro- intestinale væske, volumen, pH, motilitet og transitionstid og galdesammensætning.
Variability in exposure may also occur due to differences in gastro-intestinal fluid content, volumes, pH, motility and transition time and bile composition.
Variabiliteten i farmakokinetikken var højere i gruppen med moderat leverinsufficiens (variationskoefficienten for systemisk eksponering [AUCinf] var 50 % versus < 30 % i de andre leverfunktionsgrupper).
Pharmacokinetic variability was higher in the moderate hepatic impairment group (co-efficient of variation in systemic exposure [AUCinf] was 50% versus <30% in the other hepatic function groups).
Variabiliteten i rivaroxabans farmakokinetik er moderat med en inter-individuel variabilitet (CV%), der ligger mellem 30 % og 40 %, bortset fra på operationsdagen og dagen efter, hvor variabiliteten i eksponering er høj (70 %).
Variability in rivaroxaban pharmacokinetics is moderate with inter-individual variability (CV %) ranging from 30 % to 40 %, apart from on the day of surgery and the following day when variability in exposure is high (70 %).
Variable/ statistisk Cetuximab plus FOLFIRI
Variable/ statistic Cetuximab plus FOLFIRI
Variable/ statistisk Cetuximab plus OxMdG
Variable/ statistic Cetuximab plus OxMdG
Varianter blev selekteret ved de NS5A- resistensforbundne positioner 24, 28, 30, 31, 32, 58, 92 og 93.
Variants were selected at NS5A resistance associated positions 24, 28, 30, 31, 32, 58, 92 and 93.
Variationen i de farmakokinetiske parametre var større i ekspektorat end i serum.
The variability in pharmacokinetic parameters was higher in sputum as compared to serum.
Variationen i hæmoglobinkoncentration skal afhjælpes via dosisstyring, hvor målet er en ønsket hæmoglobinkoncentration på 10 g/dl (6,2 mmol/l) til 12 g/dl (7,5 mmol/l).
Haemoglobin variability should be addressed through dose management, with consideration for the haemoglobin target range of 10 g/dl (6.2 mmol/l) to 12 g/dl (7.5 mmol/l).
Variationen i rivaroxabans farmakokinetik er moderat med interindividuel variation (variationskoefficient) i intervallet 30-40 %.
Variability in rivaroxaban pharmacokinetics is moderate with inter-individual variability (CV%) ranging from 30% to 40%.
Variationer i farven inden for denne skala har ingen indflydelse på styrken.
Variations of colour within this range do not affect potency.
Variationskoefficient (%)
Coefficient of variation (%)
Varicella-zoster-virus, Oka/Merck-stamme, (levende, attenueret) ≥19400 PFU
Varicella-zoster virus Oka/Merck strain, (live, attenuated) ≥19400 PFU
Varicella-zoster-virus, Oka/Merck-stamme, (levende, attenueret) ≥19400 PFU
Varicella-zoster virus, Oka/Merck strain, (live, attenuated) ≥19400 PFU
Varicella-zoster-virus1, Oka/Merck-stamme, (levende, attenueret) ikke under 19400 PFU (plaqueformende enheder).
Varicella-zoster virus1, Oka/Merck strain, (live, attenuated) not less than 19400 PFU (plaque-forming units).
Varicella-zoster-virus1, Oka/Merck-stamme, (levende, attenueret) ikke under 19400 PFU2 1produceret i humane diploide (MRC-5) celler
Varicella-zoster virus1, Oka/Merck strain, (live, attenuated) not less than 19400 PFU2 1produced in human diploid (MRC-5) cells
Varicella-zoster-virus¹, Oka/Merck-stamme, (levende, attenueret) ikke under 19400 PFU (plaqueformende enheder).
Varicella-zoster virus1, Oka/Merck strain, (live, attenuated) not less than 19400 PFU (plaque-forming units).
Varicellavirus Oka/Merck stamme.........................................................≥ 3,99 log10 PFU
Varicella virus Oka/Merck strain ................................................. ≥ 3.99 log10 PFU
Varicellavirus3 Oka/Merck stamme (levende, svækket) ........................≥ 3,99 log10 PFU**
Varicella virus3 Oka/Merck strain (live, attenuated) ................... not less than 3.99 log10 PFU
Varier stedet fra dag til dag.
Vary the site from day to day.
varierende grader
degrees of
Varig responsrate
Durable response rate
varighed
Duration of treatment
Varighed (timer): Oxyglobinniveauer over 1 g/dl
Duration (hours): Oxyglobin levels over 1 g/dl
Varighed (timer): Oxyglobinniveauer over 1 g/dl
Duration hours): Oxyglobin levels over 1 g/dL
Varighed af atrieflimren
Duration of Atrial Fibrillation
Varighed af behandlingen med Revlimid
Duration of the treatment with Revlimid
Varighed af behandlingen vil være afhængig af den iagttagne virkning.
Duration of treatment will be dependent on the response observed.
Varighed af beskyttende immunitet: En enkelt vaccination er tilstrækkelig for at opnå beskyttelse i risikoperioden for infektion med Marek’s disease virus.
Duration of immunity: A single vaccination is sufficient to provide protection during the risk period of infection with Marek’s disease.
Varighed af den aktuelle svære kliniske TMA-manifestation
Duration of current severe clinical TMA manifestation
Varighed af immunitet for rabies blev påvist efter en vaccition ved 12-ugers alderen.
Duration of immunity for rabies was demonstrated after one vaccination at 12 weeks of age.
Varighed af immunitet mod Newcastle disease: til 9-ugers alderen.
Duration of immunity against Newcastle disease: 9 week of age.
Varighed af immunitet mod Newcastle disease: til 9-ugers alderen.
Duration of immunity against Newcastle disease: 9 weeks of age.
Varighed af immunitet opnået efter vaccinationsprogrammet:
Duration of immunity induced by the vaccination scheme:
Varighed af immunitet: 1 år efter basisvaccination,
Duration of immunity: one year after the primary vaccination for all components.
Varighed af immunitet: 1 år efter basisvaccination,
The duration of immunity is one year after the primary vaccination for all components.
Varighed af immunitet: 1 år efter primær vaccinationsprogram
The duration of immunity is 1 year after primary vaccination course.
Varighed af immunitet: 1år efter den sidste (gen-)vaccination.
Duration of immunity: 1 year after the last (re-)vaccination.
Varighed af immunitet: 23 uger efter vaccination (PCV2)
Duration of immunity: 23weeks after vaccination (PCV2)
Varighed af immunitet: 23 uger efter vaccination (PCV2).
Duration of immunity: 23 weeks after vaccination (PCV2)
Varighed af immunitet: 26 dage efter det primære vaccinations program
Duration of immunity: 26 days after the primary vaccination course
Varighed af immunitet: 4 måneder hos grise, der blev vaccineret i alderen mellem 56 og 96 dage.
Duration of immunity: 4 months in pigs vaccinated between the age of 56 and 96 days and
Varighed af immunitet: mindst 14 uger efter vaccination.
Duration of immunity: at least 14 weeks after vaccination.
Varighed af immunitet: op til 5 uger efter overførsel af passive antistoffer gennem optagelse af kolostrum.
Duration of immunity: up to 5 weeks after transfer of passive antibodies through colostrum intake.
Varighed af immunitet: seks måneder
Duration of immunity: six months.
Varighed af immunrespons
Persistence of immune response
Varighed af immunrespons hos børn i alderen 2-10 år
Persistence of immune response in children aged 2-10 years
Varighed af immunrespons hos børn i alderen 6-10 år
Persistence of immune response in children aged 6-10 years
Varighed af immunrespons hos småbørn i alderen 12-23 måneder
Persistence of immune response in toddlers aged 12-23 months
Varighed af immunrespons hos unge i alderen 11-17 år
Persistence of immune response in adolescents aged 11-17 years of age
Varighed af MaHR (%; Kaplan-Meier-estimater)
Duration of MaHR (%; Kaplan-Meier estimates)
Varighed af MCyRb
Duration of MCyRb
Varighed af monitoreringen af patienter efter administration.
Duration of monitoring of patients after administration.
Varighed af objektivt respons (måneder)
Duration of objective response (months)
Varighed af resistensrelaterede substitutioner
Persistence of resistance–associated substitutions
Varighed af respons - (måneder)h
Duration of response  (months)h
Varighed af respons i begge responsgrupper varierede mellem 4,7 og 36,4 uger, samlet median overlevelse var 13,1 uger [95 % CI: 8,7 – 17,4], og overlevelse efter 1 år var 14 % [95 % CI: 3 % – 26 %].
Duration of response in both classifications of response ranged between 4.7 and 36.4 weeks and median overall survival was 13.1 weeks [95 % CI: 8.7–17.4] and survival at one year was 14 % [95 % CI: 3 %–26 %].